TPST vs. HOOK, JAGX, RLYB, SCYX, MRNS, IFRX, ASMB, VTVT, MNOV, and DERM
Should you be buying Tempest Therapeutics stock or one of its competitors? The main competitors of Tempest Therapeutics include Hookipa Pharma (HOOK), Jaguar Health (JAGX), Rallybio (RLYB), SCYNEXIS (SCYX), Marinus Pharmaceuticals (MRNS), InflaRx (IFRX), Assembly Biosciences (ASMB), vTv Therapeutics (VTVT), MediciNova (MNOV), and Journey Medical (DERM). These companies are all part of the "pharmaceutical preparations" industry.
Tempest Therapeutics (NASDAQ:TPST) and Hookipa Pharma (NASDAQ:HOOK) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their profitability, dividends, community ranking, analyst recommendations, earnings, risk, valuation, institutional ownership and media sentiment.
In the previous week, Hookipa Pharma had 2 more articles in the media than Tempest Therapeutics. MarketBeat recorded 4 mentions for Hookipa Pharma and 2 mentions for Tempest Therapeutics. Hookipa Pharma's average media sentiment score of 0.74 beat Tempest Therapeutics' score of 0.72 indicating that Hookipa Pharma is being referred to more favorably in the news media.
Tempest Therapeutics has higher earnings, but lower revenue than Hookipa Pharma. Tempest Therapeutics is trading at a lower price-to-earnings ratio than Hookipa Pharma, indicating that it is currently the more affordable of the two stocks.
22.5% of Tempest Therapeutics shares are held by institutional investors. Comparatively, 63.9% of Hookipa Pharma shares are held by institutional investors. 3.3% of Tempest Therapeutics shares are held by company insiders. Comparatively, 5.8% of Hookipa Pharma shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Tempest Therapeutics has a net margin of 0.00% compared to Hookipa Pharma's net margin of -88.73%. Hookipa Pharma's return on equity of -33.33% beat Tempest Therapeutics' return on equity.
Tempest Therapeutics has a beta of -1.65, suggesting that its share price is 265% less volatile than the S&P 500. Comparatively, Hookipa Pharma has a beta of 0.92, suggesting that its share price is 8% less volatile than the S&P 500.
Tempest Therapeutics presently has a consensus target price of $25.00, suggesting a potential upside of 686.16%. Hookipa Pharma has a consensus target price of $4.67, suggesting a potential upside of 472.32%. Given Tempest Therapeutics' higher probable upside, equities analysts clearly believe Tempest Therapeutics is more favorable than Hookipa Pharma.
Tempest Therapeutics received 8 more outperform votes than Hookipa Pharma when rated by MarketBeat users. However, 69.11% of users gave Hookipa Pharma an outperform vote while only 64.14% of users gave Tempest Therapeutics an outperform vote.
Summary
Hookipa Pharma beats Tempest Therapeutics on 11 of the 16 factors compared between the two stocks.
Get Tempest Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for TPST and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding TPST and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Tempest Therapeutics Competitors List
Related Companies and Tools
